HOME ABOUT US PRINT PUBLICATIONS SUBSCRIPTIONS CONTACT US RSS
 
Subscriber Sign In
 
Today@FDA
FDA Calendar
 
Archived Daily Updates
 
FDA Whistleblower
 
What do you think?
Search our 64,388-story database
Search
Renew subscription










E-mail This to a Friend | Print Format  
     
 
Drug Development Landscape Evolving
05/16/2019
 

Iqvia Institute for Human Data Science says that over the next five years, clinical trial productivity will be heavily influenced by trends like biomarkers, pre-screened patient pools, and predictive analytics. The projection is in a white paper, “The Changing Landscape of Research and Development.”

The analysis indicates that ongoing changes in the clinical development process led to a record number of drug approvals in 2018, with 59 novel treatments reaching patients in the U.S. alone.

The study assesses the current activity within research and development, the productivity levels of the clinical development process, and how key trial trends will transform clinical development over the next five years.

Key sections of the report look at new drug approvals and launches, clinical development pipeline, clinical trial activity, drivers of change in clinical development, and modeling future trial productivity.


Post an instant comment on this report here

 
Any copying or electronic transfer without written permission is strictly prohibited and will result
in termination of service and prosecution under the federal Copyright Act.
To gain permission to copy this article log on to http://www.copyright.com.

FERDIC INCORPORATED - P.O. Box 28, Camp Hill, PA 17001 | Phone: (717)731-1426 fax:(717)731-1427 Email: info@fdaweb.com